Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
lol!! To funny
And I'm with you my friend.
I’m with you my friend
Hoping and praying we turn the page here after the merger.
Now i know why you're always up late watching movies.
Yes and the volume is also building.
Hey, I still get excited over that. LOL!!
I haven't been this excited since the time I was 16 and the movie I was watching showed a boob.
We are going to find out thats for sure
Our RXMD investments are in hospice care.
Think back to when things were great, when Ms Mars was CEO. Integrity, value, optimism.
Then Charlie took over. He takes our money, gives us a needle filled with fluid he says will eventually make us happy. He then ghosts us. We wake up in an alley, HIV positive, thinking back to the good old days with Mars.
RIP RXMD
We either die wealthy men, or we die broke as fk. Same as it ever was.
Nostradamus speaking? 🤔
Pretty strong statement. What exactly are you expecting Cleo
I would advise everyone spend time with loved ones and really take it all in for the next few days.
Our lives are about to change forever.
lol! I love your optimism
I would think Friday the 13th
I am so confident that I've already submitted my two weeks notice.
I'm wondering which day 🤔
Maybe Fri morning before the opening bell.
Yes this is the week
Hopefully for the first time in years we won’t be disappointed but I don’t have high hopes
Well, here we are finally! The week we've been looking towards or the week some on here have dreaded. Either way, it's finally here. GLTA
The Healthcare industry is getting hammered, hence the closures we have been seeing. The rich love buying things cheap, so I would hope they have found some good businesses to pick up in the industry.
Looks like the charts agree with you.
Sure hope so garrox.
With M/A specialists on BoD , I believe something is already in the works. Hopefully Fernandez will show some guidance this Friday.
Hopefully after this merger is comple, he announces a M/A with a Healthcare company. He has had time. He has the cash on hand.
That would be ideal colorful. Have a good one.
After rxmd move to Nasdaq they should have many ways to pump it up unless they have another plot to keep it low, such as to RS again, otherwise we should enjoy the upward momentum.
Me too. Being a mechanic isn't living the dream. Show me the money.
They have control shares , so we should know the " vote" result . After the merger , we have more shares but less value ? or they just print more paper for you then share RXMD property and profit ?
I would like to see the Fair Value increase after the merger. First, Mr Fernandez needs to provide future guidance on where the company is headed.
I'll take half of fair value. But of course that's all a pipe dream here.
What is the Fair Price of RXMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
94.7%
Undervalued
Current Price
US$1.95
Fair Value
US$36.87
20% Undervalued
About Right
20% Overvalued
Data
Learn
Below Fair Value: RXMD ($1.95) is trading below our estimate of fair value ($36.87)
Significantly Below Fair Value: RXMD is trading below fair value by more than 20%.
LOL..."Like Armen is not Involved here". Too Funny!!!!
There has to be some news, its been years.
News out!!
ncreases to CEO Compensation Might Be Put On Hold For Now at NextPlat Corp (NASDAQ:NXPL)
Key Insights
NextPlat's Annual General Meeting to take place on 13th of September
Salary of US$468.0k is part of CEO Charles Fernandez's total remuneration
The total compensation is 771% higher than the average for the industry
Over the past three years, NextPlat's EPS grew by 66% and over the past three years, the total loss to shareholders 80%
In the past three years, the share price of NextPlat Corp (NASDAQ:NXPL) has struggled to grow and now shareholders are sitting on a loss. What is concerning is that despite positive EPS growth, the share price has not tracked the trend in fundamentals. These are some of the concerns that shareholders may want to bring up at the next AGM held on 13th of September. They could also influence management through voting on resolutions such as executive remuneration. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment.
View our latest analysis for NextPlat
Comparing NextPlat Corp's CEO Compensation With The Industry
Our data indicates that NextPlat Corp has a market capitalization of US$23m, and total annual CEO compensation was reported as US$3.3m for the year to December 2023. We note that's an increase of 33% above last year. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$468k.
In comparison with other companies in the American Telecom industry with market capitalizations under US$200m, the reported median total CEO compensation was US$376k. Accordingly, our analysis reveals that NextPlat Corp pays Charles Fernandez north of the industry median. What's more, Charles Fernandez holds US$4.8m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.
On an industry level, roughly 17% of total compensation represents salary and 83% is other remuneration. In NextPlat's case, non-salary compensation represents a greater slice of total remuneration, in comparison to the broader industry. It's important to note that a slant towards non-salary compensation suggests that total pay is tied to the company's performance.
NextPlat Corp's Growth
NextPlat Corp has seen its earnings per share (EPS) increase by 66% a year over the past three years. It achieved revenue growth of 499% over the last year.
Shareholders would be glad to know that the company has improved itself over the last few years. The combination of strong revenue growth with medium-term EPS improvement certainly points to the kind of growth we like to see. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
Has NextPlat Corp Been A Good Investment?
Few NextPlat Corp shareholders would feel satisfied with the return of -80% over three years. So shareholders would probably want the company to be less generous with CEO compensation.
In Summary...
Despite the growth in its earnings, the share price decline in the past three years is certainly concerning. A huge lag in share price growth when earnings have grown may indicate there could be other issues that are affecting the company at the moment that the market is focused on. If there are some unknown variables that are influencing the stock's price, surely shareholders would have some concerns. These concerns should be addressed at the upcoming AGM, where shareholders can question the board and evaluate if their judgement and decision making is still in line with their expectations.
We can learn a lot about a company by studying its CEO compensation trends, along with looking at other aspects of the business. That's why we did our research, and identified 2 warning signs for NextPlat (of which 1 is concerning!) that you should know about in order to have a holistic understanding of the stock.
Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.??This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session?You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
Honestly, IDK, I've been burned so many times with this stock so who knows? I'd say it will be a none effect unless some noteworthy news comes out from the company.
So, whats everyones projection here? Maybe the market likes the merger and price moves north? Maybe management has news to drop immediately following the merger?
Well it’s clear that Rodney didn’t sell those shares on the open market or through a form 4. If that site is real or accurate were those shares sold via private placement.
We don't even know if one exists. But they are used to protect company secrets, policies, methods of operation, etc.
I find it somewhat reassuring that there are no sells for NXPL.
https://m.insidertracking.com/node/7?menu_tickersearch=nxpl
If this is saying what I believe it is then Rodney has made quite a bit of money in this venture, and stands to make a lot more. If he's making this as #2 how much is #1 making?
https://m.insidertracking.com/node/7?menu_tickersearch=rxmd
But what would be the need for an NDA? /s
Exactly right, only Armen (besides Chucky) would know that. And with Armen not responding here now tells me MrMike could be on something. But again next week we'll know a lot more about what's going on.
GLTA
You may be right. If Armen signed a NDA then it could cause him legal peril if he discloses anything that could be deemed to violate an NDA, if one actually exists.
If he's (Armen) a common shareholder now, I don't see how Chucky Boy can say or do anything unless Armen signed some sort of "legal" document, and I would think Armen would know if he did or not before ranting on here.
But who knows...
Next week should be the tell-all for us.
GLTA
Followers
|
746
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
196053
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |